Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2012;7(5):e38189.
doi: 10.1371/journal.pone.0038189. Epub 2012 May 30.

Human mesenchymal stem cells protect human islets from pro-inflammatory cytokines

Affiliations

Human mesenchymal stem cells protect human islets from pro-inflammatory cytokines

Telford Y Yeung et al. PLoS One. 2012.

Abstract

Transplantation of human islets is an attractive alternative to daily insulin injections for patients with type 1 diabetes. However, the majority of islet recipients lose graft function within five years. Inflammation is a primary contributor to graft loss, and inhibiting pro-inflammatory cytokine activity can reverse inflammation mediated dysfunction of islet grafts. As mesenchymal stem cells (MSCs) possess numerous immunoregulatory properties, we hypothesized that MSCs could protect human islets from pro-inflammatory cytokines. Five hundred human islets were co-cultured with 0.5 or 1.0 × 10(6) human MSCs derived from bone marrow or pancreas for 24 hours followed by 48 hour exposure to interferon-γ, tumor necrosis factor-α and interleukin 1β. Controls include islets cultured alone (± cytokines) and with human dermal fibroblasts (± cytokines). For all conditions, glucose stimulated insulin secretion (GSIS), total islet cellular insulin content, islet β cell apoptosis, and potential cytoprotective factors secreted in the culture media were determined. Cytokine exposure disrupted human islet GSIS based on stimulation index and percentage insulin secretion. Conversely, culture with 1.0 × 10(6) bMSCs preserved GSIS from cytokine treated islets. Protective effects were not observed with fibroblasts, indicating that preservation of human islet GSIS after exposure to pro-inflammatory cytokines is MSC dependent. Islet β cell apoptosis was observed in the presence of cytokines; however, culture of bMSCs with islets prevented β cell apoptosis after cytokine treatment. Hepatocyte growth factor (HGF) as well as matrix metalloproteinases 2 and 9 were also identified as putative secreted cytoprotective factors; however, other secreted factors likely play a role in protection. This study, therefore, demonstrates that MSCs may be beneficial for islet engraftment by promoting cell survival and reduced inflammation.

PubMed Disclaimer

Conflict of interest statement

Competing Interests: The authors have declared that no competing interests exist.

Figures

Figure 1
Figure 1. Protection of human islets from cytokine induced apoptosis by bone marrow derived MSCs.
A-C) 500 Islets, D-F) 500 Islets + cytokines, G-I) 500 Islets +1.0×106 bMSCs, + cytokines. Tissues were stained for insulin (A,D,G) in red and TUNEL (B,E,H) in green. The merge of the red and green images are presented in panels C, F, and I. Islets cultured without cytokines demonstrated minimal TUNEL positive cells. After cytokine exposure, the number of TUNEL positive cells increased; TUNEL and insulin co-expression was also increased with cytokine treatment. Alteration of native islet organization was observed. After cytokine exposure, co-expression of insulin and TUNEL did not increase in the islets + bMSCs group; cytokines – cocktail of IFNγ, TNFα and IL-1β described in materials and methods. Scale bar represents 100 µm.

Comment in

References

    1. Shapiro AM, Ricordi C, Hering BJ, Auchincloss H, Lindblad R, et al. International trial of the Edmonton Protocol for islet transplantation. N Engl J Med. 2006;355:1318–1330. - PubMed
    1. Shapiro AMJ, Lakey JR, Ryan EA, Korbutt GS, Toth E, et al. Islet transplantation in seven patients with type 1 diabetes mellitus using a glucocorticoid-free immunosuppressive regimen. N Engl J Med. 2000;343:230–238. - PubMed
    1. Ryan EA, Paty BW, Senior PA, Bigam D, Alfadhli E, et al. Five-year follow-up after clinical islet transplantation. Diabetes. 2005;54:2060–2069. - PubMed
    1. Street CN, Lakey JRT, Shapiro AMJ, Imes S, Rajotte RV, et al. Islet graft assessment in the Edmonton Protocol. Implications for predicting long term clinical outcome. Diabetes. 2004;53:3107–3114. - PubMed
    1. Barshes NRWyllieS, Goss JA. Inflammation mediated dysfuntion and apoptosis in pancreatic islet transplanation: implications for intrahepatic grafts. J Leuko Bio. 2005;77:587–597. - PubMed

Publication types

MeSH terms